You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Indonesia first nation to green light Novavax Covid-19 vaccine

Indonesia first to green light Novavax COVID-19 vaccine

Topics
Coronavirus | Coronavirus Vaccine | Coronavirus Tests

AP  |  Jakarta 

FILE - This Wednesday, Oct. 7, 2020 file photo shows a vial of the Phase 3 Novavax coronavirus vaccine ready for use in a trial at St. George's University hospital in London. (Photo: AP)
FILE - This Wednesday, Oct. 7, 2020 file photo shows a vial of the Phase 3 Novavax coronavirus vaccine ready for use in a trial at St. George's University hospital in London. (Photo: AP)

Biotechnology company Novavax said Monday that Indonesia has given the world's first emergency use authorisation for its COVID-19 vaccine, which uses a different technology than currently used shots.

The vaccine doesn't require the extremely cold storage temperatures that some other vaccines need, which could allow it to play an important role in boosting supplies in poorer countries around the world.

The two-dose Novavax vaccine is made with lab-grown copies of the spike protein that coats the That's very different from widely used mRNA vaccines such as Pfizer and Moderna that deliver genetic instructions for the body to make its own spike protein.

The emergency authorization of the vaccine is a very important step for Indonesia's COVID-19 vaccination programme, Indonesian epidemiologist Dicky Budiman said.

This vaccine will be much easier to transport, store and distribute in a place like Indonesia, where we have many islands, he said.

Budiman said if the rollout of the vaccine is successful, it could lead to its approval and use in other developing nations.

The need for more vaccines remains critical in many countries, including Indonesia.

In June, U.S.-based Novavax announced the vaccine had proven about 90% effective against symptomatic COVID-19 in a study of nearly 30,000 people in the U.S. and Mexico. It also worked against variants circulating in those countries at the time, it said.

The company said side effects were mild and included tenderness at the injection site, headache, aches and pains and fatigue.

In October, it addressed concerns that production of the vaccine had been slowed due to a lack of raw materials and other issues, saying it planned to achieve a capacity of 150 million doses per month by the end of the fourth quarter through partnerships with Serum Institute of India, SK Bioscience in South Korea and Takeda in Japan, among others.

Novavax said it has already filed for authorisation of the vaccine in the United Kingdom, European Union, Canada, Australia, India and the Philippines.

Indonesia was battered by a deadly wave of COVID-19 fueled by the delta variant and post-holiday travel from June through August. New cases have now dropped, averaging less than 1,000 a day since mid October.

About 36% of people in Indonesian have received two doses of a vaccine, and about 58% have received one dose, according to the Ministry of Health.

Over 143,400 people have died from the virus in Indonesia. The number is thought to be an undercount due to low testing and tracing.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, November 01 2021. 17:56 IST
RECOMMENDED FOR YOU